A comparison of the blood pressure changes of lumiracoxib with those of ibuprofen and naproxen
JournalArticle (Originalarbeit in einer wissenschaftlichen Zeitschrift)
 
ID 1196437
Author(s) Farkouh, Michael E; Verheugt, Freek W A; Ruland, Sean; Kirshner, Howard; Jeger, Raban; Gitton, Xavier; Krammer, Gerhard; Stricker, Kirstin; Sallstig, Peter; Mellein, Bernhard; Matchaba, Patrice; Chesebro, James H
Author(s) at UniBasel Jeger, Raban
Year 2008
Title A comparison of the blood pressure changes of lumiracoxib with those of ibuprofen and naproxen
Journal Journal of clinical hypertension
Volume 10
Number 8
Pages / Article-Number 592-602
Abstract The 52-week Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET) investigated the gastrointestinal and cardiovascular safety profile of lumiracoxib 400 mg once daily compared with 2 traditional nonsteroidal anti-inflammatory drugs (NSAIDs): ibuprofen 800 mg 3 times daily and naproxen 500 mg twice daily. Data from TARGET were analyzed to examine the effect of lumiracoxib compared with ibuprofen and naproxen on blood pressure (BP), incidence of de novo and aggravated hypertension, prespecified edema events, and congestive heart failure. Lumiracoxib resulted in smaller changes in BP as early as week 4. Least-squares mean change from baseline at week 4 for systolic BP was +0.57 mm Hg with lumiracoxib compared with +3.14 mm Hg with ibuprofen (P<.0001) and +0.43 with lumiracoxib compared with +1.80 mm Hg with naproxen (P<.0001). In conclusion, the use of lumiracoxib and traditional NSAIDs results in differing BP changes; these might be of clinical relevance.
Publisher Elsevier
ISSN/ISBN 0748-450X
edoc-URL http://edoc.unibas.ch/dok/A6006608
Full Text on edoc No
Digital Object Identifier DOI 10.1111/j.1751-7176.2008.07802.x
PubMed ID http://www.ncbi.nlm.nih.gov/pubmed/18772641
ISI-Number WOS:000261100000002
Document type (ISI) Journal Article, Randomized Controlled Trial
 
   

MCSS v5.8 PRO. 0.445 sec, queries - 0.000 sec ©Universität Basel  |  Impressum   |    
10/08/2020